STOCK TITAN

Matthew Gline sells $8.44M in ROIV stock (ROIV) — insider Form 144 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Rockefeller Financial LLC and related parties reported proposed and recent sales of Common Stock. The excerpt lists proposed dispositions of 43,493 shares (CVAR grant, dated 03/30/2026) and 246,281 RSUs (grant dated 07/26/2024) with settlement dates in late March 2026. It also reports sales by Matthew Gline on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.

Positive

  • None.

Negative

  • None.

Insights

Routine resale disclosure listing proposed and completed insider share sales.

The filing lists planned dispositions tied to prior grants (a CVAR grant and RSU grant) and two completed sales by a reporting person on 03/30/2026 with precise share counts and proceeds. These entries record transfers and proceeds; they do not provide company guidance or balance-sheet changes.

Watch for subsequent filings that may disclose additional holder identities or confirm settlement mechanics; timing and cash‑flow recipients are not detailed in the excerpt.

Proposed CVAR-related shares 43,493 shares CVAR Grant dated 03/26/2020 with disposition date 03/30/2026
Proposed RSU disposition 246,281 RSUs RSU Grant dated 07/26/2024 with disposition date 03/31/2026
Sale by Matthew Gline — lot 1 53,826 shares Sold 03/30/2026 for $1,421,544.66
Sale by Matthew Gline — lot 2 304,684 shares Sold 03/30/2026 for $8,439,746.80
Form 144 regulatory
"144: Securities To Be Sold"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
RSU financial
"RSU Grant - Grant date 07/26/2024"
Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.
CVAR Grant financial
"CVAR Grant - Grant Date 03/26/2020"

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What transactions does ROIV disclose in this Form 144 excerpt?

Answer: The excerpt shows proposed dispositions of 43,493 shares and 246,281 RSUs, plus two sales by Matthew Gline. It records sales on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.

Who reported the recent share sales in the ROIV filing?

Answer: The excerpt identifies Matthew Gline as the reporting person for the completed sales on 03/30/2026. The filer/issuer information lists Rockefeller Financial LLC in connection with the common shares listed.

Do the entries show the grant dates for the securities ROIV intends to sell?

Answer: Yes. The CVAR grant referenced carries a grant date of 03/26/2020, and the RSU grant referenced shows a grant date of 07/26/2024, with disposition dates in March 2026.

Are proceeds and per‑share prices provided for the reported ROIV sales?

Answer: The excerpt supplies aggregate proceeds for two completed sales: $1,421,544.66 (53,826 shares) and $8,439,746.80 (304,684 shares). Per‑share prices are not explicitly listed as single‑share amounts in the excerpt.

Does this Form 144 excerpt state who receives the sale proceeds for ROIV?

Answer: The excerpt provides aggregate proceeds for reported sales but does not state who receives the proceeds or the cash‑flow treatment. The filing text in the excerpt does not specify recipient details.